# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126282
Filing Date
2024-11-13
Accepted
2024-11-13 16:04:17
Documents
59
Period of Report
2024-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | antx-20240930.htm iXBRL | 10-Q | 2248907
2 | EX-31.1 | antx-ex31_1.htm | EX-31.1 | 17361
3 | EX-31.2 | antx-ex31_2.htm | EX-31.2 | 17656
4 | EX-32.1 | antx-ex32_1.htm | EX-32.1 | 8403
5 | EX-32.2 | antx-ex32_2.htm | EX-32.2 | 8218
| Complete submission text file | 0000950170-24-126282.txt |  | 7473293

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | antx-20240930.xsd | EX-101.SCH | 959281
62 | EXTRACTED XBRL INSTANCE DOCUMENT | antx-20240930_htm.xml | XML | 1100097

Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41331 | Film No.: 241453931
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)